Patents Examined by Q. Janice Li
-
Patent number: 7803582Abstract: A recombinant vector for delivering A3G genes into human cells comprising (i) a gene expression block including an A3G gene selected from a wild type A3G gene represented by SEQ ID NO: 1 and a mutant A3G gene and (ii) a group of elements from a modified lentiviral vector including lentiviral regions of packaging signal (?, psi), LTRs, RRE, and PBS; wherein said A3G gene is operably linked to the packaging signal (?, psi), LTRs, RRE, and PBS.Type: GrantFiled: March 17, 2007Date of Patent: September 28, 2010Inventor: Hongzhan Xu
-
Patent number: 7795027Abstract: Described are preferred extracellular matrix composites including a first extracellular matrix material having a second extracellular matrix material deposited thereon. The preferred materials are made by culturing cells in contact with an extracellular matrix graft material in a fashion to cause the cells to biosynthesize and deposit extracellular matrix components on the material. The cells are then removed to provide the extracellular matrix composite material.Type: GrantFiled: March 3, 2006Date of Patent: September 14, 2010Assignee: Cook Biotech IncorporatedInventor: Michael C Hiles
-
Patent number: 7794702Abstract: This invention provides a composition for delivery of a gene to a syncytial structure comprising stem cells incorporated with the gene. This invention also provides a composition for ion channel transfer which comprises stem cells incorporated with a compound in an amount sufficient to create ion channels. This invention also provides for a method of expressing a functional gene product in a syncytial structure comprising administering a composition, comprising stem cells that have been incorporated with a gene, to the syncytial structure. This invention further provides a method of expressing a functional ion channel in a syncytial structure comprising administering a composition, comprising stem cells that have been incorporated with a compound in an amount sufficient to create ion channels, to the syncytial structure. This invention also provides a composition for delivery of small molecules comprising stem cells incorporated with the small molecules or genes encoding the small molecules.Type: GrantFiled: January 15, 2003Date of Patent: September 14, 2010Assignees: The Trustees of Columbia University in the City of New York, The Research Foundation of State University of New YorkInventors: Michael R. Rosen, Richard B. Robinson, Ira S. Cohen, Peter Brink
-
Patent number: 7786088Abstract: The present invention relates to the targeted delivery of a delivery vehicle construct which specifically binds to and stimulates endocytosis into cells expressing the urokinase plasminogen activator receptor (uPAR), and particularly human airway epithelia. The delivery vehicle construct comprises a portion of uPA and a cargo linked thereto and is useful for the targeted delivery of the cargo to a cell. In one aspect of the invention, the uPA portion of the delivery vehicle construct comprises the wild-type uPA, a fragment of uPA which has the PAI-1 binding region deleted, or a uPA peptide comprising amino acids 13-19 and is useful for the targeted delivery of the cargo to cells, and in particular to airway epithelia. The present invention also provides a method for delivering the delivery vehicle construct to a cell.Type: GrantFiled: August 30, 2006Date of Patent: August 31, 2010Assignee: University of Iowa Research FoundationInventors: Michael J. Welsh, Paola T. Drapkin
-
Patent number: 7776321Abstract: The invention relates to methods and materials useful for targeting antigenic determinants of mutable pathogens for somatic hypermutation. These methods and materials can be used to induce an immune response against antigenic variants of mutable pathogens.Type: GrantFiled: September 24, 2002Date of Patent: August 17, 2010Assignee: Mayo Foundation for Medical Education and ResearchInventors: Marilia I. Cascalho, Jeffrey L. Platt
-
Patent number: 7767453Abstract: Hematopoietic stem cells and methods for ex vivo expansion of hematopoietic stem cells are provided. The methods comprise culturing the cells in a media containing an effective amount insulin-like growth factor (IGF), fibroblast growth factor (FGF), thrombopoietin (TPO), and stem cell factor (SCF), under conditions sufficient for expansion of said cells. Methods for identifying expanded hematopoeitc stem cells and kits for ex vivo expansion of hematopoietic stem cells are also provided.Type: GrantFiled: October 20, 2005Date of Patent: August 3, 2010Assignee: Whitehead Institute for Biomedical ResearchInventors: Chengcheng Zhang, Harvey Lodish
-
Patent number: 7767202Abstract: The invention provides methods and compositions for the modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules. The invention includes bi-cistronic lentiviral expression vectors adapted for antigen expression in antigen presenting cells for use in DNA vaccines directed against pathogens and tumor antigens as well as for the treatment of autoimmune disease and for the establishment of antigen tolerance.Type: GrantFiled: March 18, 2002Date of Patent: August 3, 2010Assignee: The Johns Hopkins UniversityInventors: Drew M. Pardoll, Linzhao Cheng, Yan Cui, Curt I Civin, Katherine Whartenby
-
Patent number: 7754482Abstract: The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.Type: GrantFiled: May 25, 2005Date of Patent: July 13, 2010Assignee: The Trustees of the University of PennsylvaniaInventors: James L. Riley, Carl H. June, Robert H. Vonderheide, Nicole Aqui, Megan M. Suhoski
-
Patent number: 7736641Abstract: The present invention relates to a method for treating or preventing Parkinson's disease in a patient, the method comprising administering to the patient a therapeutically effective population of neuronal cells transformed with a nucleic acid molecule encoding SRY, wherein the transformed cells express SRY.Type: GrantFiled: February 21, 2007Date of Patent: June 15, 2010Assignee: Prince Henry's Institute of Medical ResearchInventors: Vincent Russel Harley, Eric J. N. Vilain
-
Patent number: 7727763Abstract: Fetal blood multi-lineage progenitor cells that are capable of a wide spectrum of transdifferentiation are described, as well as methods of differentiating the progenitor cells into type II alveolar cells.Type: GrantFiled: April 17, 2007Date of Patent: June 1, 2010Assignees: BioE, LLC, Regents of the University of MinnesotaInventors: David H. McKenna, Jr., Barbara M. Tigges, Michael J. Berger
-
Patent number: 7723111Abstract: The present invention relates to preventive, therapeutic, and diagnostic compositions and methods employing lymphocytes having T-cell receptors and chimeric receptors. In particular, the invention relates to pre-selected dual-specificity lymphocytes having endogenous T-cell receptors and chimeric T-cell receptors that recognize a strong antigen and tumor associated antigens where the pre-selected population of adoptively transferred lymphocytes is activated by in vivo immunization, thereby increasing the effectiveness of adoptive immunotherapy.Type: GrantFiled: March 9, 2001Date of Patent: May 25, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Patrick Hwu, Michael H. Kershaw, Steven A. Rosenberg
-
Patent number: 7723103Abstract: Vector preparations and cloning constructs suitable for use in cloning are provided. Vector preparations are double-stranded DNA molecules having two 3? termini, each terminus having a single base pair overhang that is capable of hybridizing to a single base pair overhang on a double stranded polynucleotide sequence to be cloned. The overhang of the vector preparation is suitably a dCMP and the overhang of the polynucleotide sequence to be cloned is suitably a dGMP. In other embodiments, the overhang of the polynucleotide sequence to be cloned is any ddNTP and the corresponding overhang of the vector preparation is any base that pairs to the ddNTP. The latter embodiment is particularly suited to preparing recombinant molecules having only a single insert. Methods of cloning, methods of preparing libraries of recombinant molecules and kits for carrying out the methods are also provided.Type: GrantFiled: January 8, 2007Date of Patent: May 25, 2010Assignee: Lucigen CorporationInventors: David A. Mead, Ronald Godiska, Thomas W. Schoenfeld, Spencer Hermanson
-
Patent number: 7723112Abstract: The present invention relates to compositions and methods for characterizing, treating and diagnosing cancer. In particular, the present invention provides a cancer stem cell profile, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of cancer and in particular the targeting of solid tumor stem cells.Type: GrantFiled: October 31, 2006Date of Patent: May 25, 2010Assignees: The Regents of the University of Michigan, OncoMed Pharmaceuticals, Inc.Inventors: Michael F. Clarke, Tim Hoey, Xinhao Wang, Scott Dylla, Austin Gurney, Piero Dalerba, Mark Prince, Grace Chen
-
Patent number: 7705196Abstract: Tumor formation and reduced transcription of both sFRP1 gene and sFRP2 gene were found in Dlg gene knock-out mice, and thereby the following has been provided: an agent for enhancing the expression and/or function of sFRP, containing a compound having an effect of enhancing the expression and/or function of Dlg; an agent for inhibiting tumor formation or an agent for preventing and/or treating a tumor disease, containing the agent for enhancing the expression and/or function of sFRP; a method of enhancing the expression and/or function of sFRP, comprising enhancing the expression and/or function of Dlg; a method of inhibiting tumor formation or a method of preventing and/or treating a tumor disease, comprising using the aforementioned enhancing agent or the aforementioned enhancing method; a non-human mammal that is deficient in one or both of Dlg alleles; a cell originating in the mammal; a method of identifying a compound, comprising using the mammal or the cell; and a method of examining a tumor tissue orType: GrantFiled: March 30, 2005Date of Patent: April 27, 2010Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Tetsu Akiyama, Takefumi Ishidao, Tomoiki Aiba
-
Patent number: 7704964Abstract: The present invention relates to compositions and methods for selectively expressing a polypeptide in a membrane vesicle. The invention also relates to genetic constructs and recombinant cells suitable to produce such membrane vesicles. This invention also relates to such functionalized membrane vesicles as well as to methods of making antibodies, methods of producing or regulating an immune response as well as to methods of screening or identifying binding partners using the same. The invention more particularly uses lactadherin or portions thereof to selectively express polypeptides in membrane vesicles, of natural or synthetic origin. This invention can be used in experimental, research, therapeutic, prophylactic or diagnostic areas.Type: GrantFiled: August 14, 2002Date of Patent: April 27, 2010Assignee: Exothera L.L.C.Inventors: Alain Delcayre, Jean-Bernard Le Pecq
-
Patent number: 7700108Abstract: An inducer of cytotoxic T cells comprising as an active ingredient a protein which comprises the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2, or a peptide derived from the protein above is provided.Type: GrantFiled: September 19, 2003Date of Patent: April 20, 2010Assignees: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Noriyuki Sato, Tomohide Tsukahara, Yuki Nabeta, Satoshi Kawaguchi, Hideyuki Ikeda, Takuro Wada, Toshihiko Yamashita
-
Patent number: 7700824Abstract: A non-human animal which has a reduced amount of functional TAZ polypeptide and/or TAZ-like polypeptide, or a reduced amount of nucleic acid encoding said polypeptide. A method for generating a non-human animal which develops PKD comprising reducing the amount of functional TAZ polypeptide and/or TAZ-like polypeptide, or nucleic acid encoding said polypeptide. A method of screening for compounds of use in preventing or treating PKD wherein a non-human animal is administered with a test compound and the effect of the test compound on the amount or function of TAZ polypeptide and/or a TAZ-like polypeptide and/or a polypeptide regulated by TAZ or a TAZ-like polypeptide function, or the amount of nucleic acid encoding said polypeptide, is assessed.Type: GrantFiled: August 3, 2005Date of Patent: April 20, 2010Assignee: Agency for Science, Technology and ResearchInventors: M. Zakir Hossain, Walter Hunziker
-
Patent number: 7700090Abstract: The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.Type: GrantFiled: December 28, 2006Date of Patent: April 20, 2010Assignee: Anthrogenesis CorporationInventors: Mohammad Heidaran, Jia-Lun Wang, Qian Ye, Andrew Zeitlin, Colleen Suzanne Dulaney
-
Patent number: 7692059Abstract: Methods for generating and using novel overexpression activity alleles of a gene in any organism, especially Drosophilia, are provided. Such alleles may be utilized in screening assays, and used to generate dominant-negative forms of bacterial toxins.Type: GrantFiled: March 20, 2007Date of Patent: April 6, 2010Assignee: The Regents of the University of CaliforniaInventors: Ethan Bier, Annabel Guichard, Shaila Srinivasan
-
Patent number: 7687057Abstract: A method of delivering a gene product to a recipient, the method comprises (a) providing a micro-organ explant expressing at least one recombinant gene product, the micro-organ explant comprising a population of cells, the micro-organ explant maintaining a microarchitecture and a three dimensional structure of an organ from which it is obtained and at the same time having dimensions selected so as to allow diffusion of adequate nutrients and gases to cells in the micro-organ explant and diffusion of cellular waste out of the micro-organ explant so as to minimize cellular toxicity and concomitant death due to insufficient nutrition and accumulation of the waste in the micro-organ explant, at least some of the cells of the population of cells of the micro-organ explant expressing at least one recombinant gene product; and (b) implanting the micro-organ explant in the recipient.Type: GrantFiled: December 17, 2002Date of Patent: March 30, 2010Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventor: Eduardo N. Mitrani